Covington & Burling LLP | Biographies | Peter A. Laveran-Stiebar

Peter Laveran is a US corporate partner who has been resident in Covington's London office for over a decade. His broad-based practice is exclusively international, and he co-heads the firm’s Africa Practice from London. He has particular transactional experience in the life sciences, media and communications sectors and has previously led the firm’s efforts in India and the Middle East.

Mr. Laveran focuses on complex cross-border projects for emerging and mature companies headquartered in the US, Europe, Africa, India, the Middle East and elsewhere, including mergers and acquisitions, joint ventures, strategic alliances, venture capital and private equity investments and other corporate finance matters. His experience includes advising multi-national companies on the planning and development of European distribution structures and other commercial arrangements, and he has directed global post-closing merger integration efforts for clients in over 75 jurisdictions. Mr. Laveran also has considerable experience advising companies in connection with their international capital raising activities including AIM IPOs and Rule 144A, Regulation S and SEC-registered offerings.

Representative Matters

Represented Meda AB on numerous acquisitions including its acquisition of a portfolio of pharmaceutical products from Jazz Pharmaceuticals and its acquisition of MidNite, an OTC sleep aid product.
Represented HaloIPT on Qualcomm’s Acquisition of its Automotive Wireless Charging Technology.
Represented funds managed by HealthpointCapital, LLC in the sale of their controlling interest in Scient'x Groupe SAS to Alphatec Holdings, Inc.
Represented Reliance Life Sciences in a $35 million investment in an MPM BioVentures Fund.
Represented Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd.’s platform technology for monoclonal antibody discovery.
Represented Dr. George Jokhtaberidze in connection with various transactions and shareholder arrangements relating to his 51% ownership interest in leading Georgian telecommunications company Magticom Ltd.
Represented HealthpointCapital Partners as a selling shareholder in Alphatec Holdings, Inc.'s underwritten public offering of 18.4 million shares of common stock for total proceeds to HealthpointCapital and Alphatec of approximately $85 million.
Represented Encysive Pharmaceuticals Inc. in connection with the acquisition of Encysive by Pfizer Inc. for an equity value of approximately $195 million.
Represented International Specialty Products, Inc. on the sale of its UK-based hydrocolloids ingredients business to FMC Corporation.

More Representative Matters